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The interaction of antigen with the surface membrane immunoglobulin (slg) 1 
of B lymphocyte, or cross-linkage of the sIg receptor by anti-Ig initiates a complex 
process whereby a resting B cell proceeds to an Ig-secreting cell via sequential 
activation, proliferation, and differentiation steps. Several groups have proposed 
models for B cell activation and differentiation that are similar in many respects, 
but  with  certain  variations  (1-10).  We  have  been  involved  in  attempting  to 
delineate the optimal signals required for induction of a resting human B cell to 
proliferate, as well as  the signals for the induction of the activated B  cells to 
differentiate. We have shown  that Staphylococcus  aureus  Cowan strain  I  (SAC) 
directly induces proliferation of human B cells, while low dose anti-# stimulates 
B cells to  express receptors for B cell growth factor (BCGF);  BCGF,  in  turn, 
drives activated B cells to proliferate. These proliferating B cells can then be 
induced  to  differentiate  into  immunoglobulin-secreting cells  (ISC)  by  B  cell 
differentiation factor (BCDF), alternatively referred to as T  cell-replacing factor 
(TRF)  (8,  9,  11-13).  Within  this  context,  the  present study was  designed to 
determine the effect, if any, of cyclosporin A  (CsA) on  the proliferation and 
differentiation of human B cells at various states of activation and to delineate 
the mechanisms of action whereby CsA inhibits proliferative and/or differentia- 
tive responses of B cells to anti-~ and SAC. 
With regard to the usage of CsA, this drug was first isolated from the fungi 
Tricoderma polysporum and C~,lindrocarpon  lucidium booth (14). CsA has a molecular 
weight of 1,202  with an  unusual cyclic endecapeptide composed of 11  amino 
acids, several of which are N-methylated, making the molecule highly lipophilic 
and hydrophobic. Subsequent studies have revealed that this drug selectively acts 
on lymphocytes to suppress immune function by noncytotoxic mechanisms (15, 
16), and it has been shown to prolong allograft survival in many species including 
man (17,  18).  CsA  has  been  reported to  inhibit  not only T  cell proliferative 
response to mitogens or alloantigens but also the induction of cytotoxic cells in 
the mixed leukocyte reaction (15, 16,  19-24). Although it has been thought that 
CsA  acted  preferentially on  T  cells  with  considerably less  effect on  B  cells, 
1 Abbreviation,s  used in  this paper: AET, 2-aminoetbylisothiouronium bromide; BCDF, B cell differ- 
entiation factor, BCE, B cell enriched; BCGF, B cell growth factor; CsA, cyclosporin A; E, erythro- 
cytes;  ISC,  immunoglobulin-secreting  cell;  PFC,  plaque-forming cells;  SAC,  Staphylococcus  aureus 
Cowan  strain  I; sIg, surface immunoglobulin; TCGF, T  cell growth factor; TRF T  cell replacing 
factor. 
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Paavonnen  et al.  (25,  26)  first claimed  that  CsA  interfered with  the ability of 
both human T  and B cells to generate Ig-producing cells. More recent studies in 
the mouse model showed that a functional B cell subset, namely B cells responsive 
to  thymus  independent-2  antigens,  are  exquisitely sensitive  to the  suppressive 
effect of CsA (27, 28). 
In the present study, we have examined the direct effects of CsA on purified 
human  B  cells and  have demonstrated a  selective drug-induced suppression  of 
the activation phase vs. the proliferative and differentiative phases of the human 
B cell cycle. 
Materials and  Methods 
Reagents.  Anti-# antibody is  the  F(ab')2 fragment of goat anti-human  heavy chain- 
specific IgM (N. L. Cappel Laboratories, Cochranville, PA). SAC is the same preparation 
as  that  used  previously (11).  CsA  was  obtained from Sandoz (Basal,  Switzerland) and 
dissolved at 10 mg/ml in absolute alcohol. This was diluted to appropriate concentrations 
with medium before use. 
Preparations  of Factors.  Monoclonal  BCGF  used  in  the  present  study  is  the  same 
preparation as previously described in detail (8). Briefly, monoclonal BCGF was obtained 
from a  human T-T hybridoma cell line, 2Bll, which was established in our laboratory 
(29). In this monoclonal BCGF preparation, there was no interleukin-2 activity as deter- 
mined by measurement of [SH]thymidine incorporation by an interleukin-2-dependent 
cell line as described by Farrar et al.  (30).  In addition, there was no BCDF activity as 
determined by measurement of the induction of plaque-forming cells (PFC) from SAC- 
stimulated normal B cells described by Falkoff et al. (11) and from an Epstein-Barr virus- 
transformed B blastoid cell line, CESS,  as described previously (31).  BCDF-containing 
supernatants were prepared by coculture of sheep erythrocyte (E) rosette-positive cells of 
multiple donors with irradiated E  rosette-negative cells  in  the presence of 2 #g/ml of 
phytohemagglutinin in serum-free medium as formulated by Mosier et al. (33). Following 
72 h  of culture, the supernatants were harvested and assayed for BCDF activity in the 
SAC system (11) and CESS system (31) as described above. These assays gave concordant 
results. The supernatants were stored at -20°C until used. 
Cell Preparations.  Human tonsils were obtained at tonsillectomy from 12- to 22-yr-old 
patients with chronic tonsillitis and were dispersed into single cell suspensions (8). Tonsillar 
mononuclear cells  were separated by the standard  Hypaque-Ficoll gradient method.  B 
cell-enriched populations (BCE) were obtained by depletion of T  cells and monocytes (8). 
Briefly, T cells were depleted by twice rosetting with 2-aminoethylisothiouronium bromide 
(AET)-treated sheep E. Monocytes were depleted by adhering 50 x  106 T  cell-depleted 
cells to plastic flasks (100 mm x  10 mm style, Falcon 3003; Becton-Dickinson and Co., 
Oxnard, CA) containing RPMI  1640 with  I% fetal calf serum for 45 min at 370C.  In 
these  BCE  populations,  there  were  >90%  sIg+  cells  determined  by  staining  with  a 
fluorescein-conjugated F(ab')2 fragment goat anti-human Ig (Cappel Laboratories); <0.1% 
sheep E receptor-positive cells as enumerated by rosetting the cells  with  AET-treated 
sheep  E;  and  <0.1%  monocytes as  determined  by  nonspecific  esterase  staining  (8). 
Tonsillar BCE suspensions were further separated into fractions according to cell-volume 
by using counterflow centrifugation-elutriation (Beckman, Model J-6B, Beckman Instru- 
ments,  Palo Alto,  CA) by the  method previously described in  detail (28) with certain 
modifications (T. L. Gerrard and A. S. Fauci, unpublished observations). Briefly, 500 x 
106 cells in  3 ml elutriator buffer (phosphate-buffered saline containing 1.25% human 
albumin and 50 #g/ml of gentamicin) were injected into the elutriator chamber and spun 
with the J-6B elutriator at a constant speed of 2,020 +  10 rpm with the countercurrent 
flow rate started at 7.5 m|/min, and increased every 200 ml by 0.5 ml/min increments. 
Each 50-ml aliquot was collected from the exit part of the elutriator centrifuge. Cellular 
volume was quantitated with a Coulter Channelyzer (Coulter Electronics, Inc., Hialeah, 
FL). Mean volume of the small  B cells used in the following experiments was  170 _+ 10 692  CYCLOSPORIN  A  AND  HUMAN  B CELL  ACTIVATION 
gm  3.  Characterization of the surface markers of fractionated cells  has been described 
elsewhere (8). 
Cell Cultures.  In order to study the effect of stimulation of B cells with anti-# on cell 
volume, cells were cultured in a  serum-free medium  (standard medium) described by 
Mosier (33).  Standard  medium  contains  50%  Isocove's modified Dulbecco's  medium 
(Gibco Laboratories, Grand Island Biological Co., Grand Island, NY) and 50% Ham's F- 
12 medium (Gibco Laboratories) added with insulin (5/~g/ml; Sigma Chemical Co., St. 
Louis,  MO),  progesterone  (3  ×  10  -s  M;  Upjohn  Laboratories,  Kalamazoo,  MI),  2- 
mercaptoethanol (5  ×  10  -5  M),  gentamycin (50 ~g/ml), and trace elements. Standard 
medium  is  0.281  osmolal,  which  is  comparable  to  that  of RPMI  1640  medium  as 
determined by a DigiMatic Osmometer (Advanced Instruments, Inc., Needham Heights, 
MA). 2 ×  106 cells were cultured with goat anti-~ antibody (15 t~g/ml) in the presence or 
absence of various concentrations of CsA,  as indicated, in  1 ml of serum-free standard 
medium  on  16-mm  diameter  flat-bottomed  tissue  culture  wells  (3524;  Costar,  Data 
Packaging, Cambridge, MA).  Control cultures were pulsed with 0.1% of ethanol, which 
is the solvent for the drug. Cells were harvested from cultares at 30-36 h as indicated, 
and recovered cells were layered on a Hypaque-Ficoll gradient and then centrifuged at 
2,500 rpm for 20 min at 4°C.  Viable cells (>90%) were removed from the interphase 
layer and washed with Hanks' Balanced Salt Solution (M. A. Bioproducts, Walkersville, 
MD), and cell volume was quantitated with a Coulter Channelyzer. 
For  determining  incorporation  of [3H]thymidine  or  [3H]uridine,  fresh  B  cells  or 
precultured B cells in serum-free medium (5 ×  104/well) were cultured with anti-t~ (15 
#g/ml), BCGF (20% vol/voi), or anti-~ plus BCGF in the presence or absence of CsA, as 
indicated, in 0.2 ml standard medium containing 10% fetal calf serum (M. A. Bioproducts) 
in flat-bottomed microtiter plates (Costar 3596). Cells cultured in the absence of CsA had 
0.1%  ethanol  added  as  previously  mentioned.  All  cultures  were  incubated  in  100% 
humidity in 5% COs in air at 37°C.  Cultures were pulsed with  1 ~Ci of [3H]thymidine 
(6.7 Ci/mM;  New England Nuclear, Boston, MA) or 1 /~Ci or [3H]uridine (42 Ci/mM; 
New England Nuclear) over various periods as indicated before harvesting, and incorpo- 
ration of [~H]thymidine or  [3H]uridine was  measured by standard  liquid  scintillation 
counting techniques after harvesting with a  Titertek cell harvester (Flow Laboratories, 
Inc., Rockville, MD). 
Assay for B cell Differentiation.  Small tonsillar B cells purified by the method described 
above were cultured for 3  d  with  SAC  (10-3%  vol/vol) in  0.2  ml  standard  medium 
containing 10% fetal calf serum in flat-bottomed microtiter plates to activate B cells to a 
state of responsiveness to BCDF (11).  BCDF-containing supernatants (10% vol/vol) with 
or without CsA at various concentrations were added to the cultures, and the number of 
ISC per well was determined in reverse hemolytic plaque assay following an additional 3 
d of culture (11). 
Results 
CsA Inhibits B  Cell Proliferative Responses to Either SAC or Anti-# Plus BCGF.  In 
order to study the effect of CsA on B  cell proliferative responses, small B cells 
obtained from tonsillar mononuclear cells were stimulated  with either SAC  or 
anti-#  plus  BCGF,  and  CsA  was  added  to  the  cultures  at  the  time  of their 
initiation  at  various  concentrations  (0.1-10,000  ng/ml).  In  control  cultures, 
0.1% of ethanol was added. As shown in Fig.  1, addition of CsA (5-1,000 ng/ 
mi) completely inhibited B cell proliferative responses to costimulation with anti- 
and  BCGF,  while  the  same  concentration  of CsA  showed  considerably  less 
inhibitory effects on SAC-induced B cell proliferation. 50% inhibition (I50) of B 
cell proliferation induced by anti-u plus BCGF was obtained by the addition of 
1-2  ng/mi  of CsA,  whereas  the  I50  of SAC-induced  B  cell proliferation.was 
obtained with 200-300 ng/ml of CsA. Cell recovery and viability of the cultures MURAGUCHI  ET AL.  693 
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FIGURE 1.  Effect of CsA on the pr~oliferative  response of small B cells to SAC and costimu- 
lation of anti-# plus BCGF. Small B cells (5 x  104/well) separated from tonsillar mononuclear 
cells were cultured with 15 #g/mi of anti-# alone (A); 25% vol/vol of BCGF alone (V); anti-# 
and BCGF with 0.1% ethanol (O); 10-s% vol/vol of SAC with 0.1% ethanol (D); anti-# plus 
BCGF and CsA (A); SAC and CsA (I). Cultures were incubated for 3 d with the addition of 
[SH]thymidine  (1 #Ci/well) over the last 16 h. Data represent the mean (± SEM) of triplicate 
cultures. 
to which CsA  (1-1,000  ng/ml)  had been added  for 36 h  were comparable to 
those of the control culture.  Addition  of more than  10  #g/ml  of CsA  to the 
cultures  resulted  in  cell death  (data  not  shown).  These data demonstrate  that 
CsA  inhibits  the  B  cell proliferative response  to costimulation  with anti-# and 
BCGF in a  noncytotoxic manner at  50- to  100-fold lower concentrations than 
are required  for suppression  of SAC-induced B  cell proliferation.  It is unclear 
whether the suppressive effects of CsA are irreversible. Preincubation of resting 
B cells with the drug for 24 h  followed by washing and stimulation with anti-# 
plus  BCGF always  resulted in  responses significantly lower than  those seen  in 
cultures preincubated with medium alone (data not shown).  However, it is still 
possible that the cells exposed to CsA might have recovered fully if cultured for 
variable periods of time in medium  before stimulation with anti-# and  BCGF. 
These experiments proved difficult and inconclusive since B cells left in culture 
without stimulation for 24-48 h generally manifest poor responses to anti-# plus 
BCGF. 
CsA Acts on B Cells at an Early Step in the Inhibition  of B Cell Proliferative  Responses 
to Costimulation  with Anti-I~ Plus BCGF.  In order to examine at which stages in 
the activation-proliferation cascade CsA acts to inhibit the proliferative response 
of B  cells to costimulation with anti-# plus BCGF, CsA (200 ng/ml) was added 
to the cultures at various times after initiation of culture in which small B  cells 
had been incubated with anti-# and  BCGF. As  shown in  Fig.  2,  CsA-mediated 
inhibition was found only when CsA was added to the cultures during the first 
24  h  of incubation.  The  addition  of CsA  after  40  h  failed  to  inhibit  B  cell 
proliferation. These results indicate that CsA acts on B  cells at an early step in 
the inhibition of proliferative responses to costimulation with anti-# plus BCGF. 
CsA  Inhibits  the  Anti-#dnduced  Cell  Enlargement  of Small  B  Cells.  We  have 
recently shown that in the costimulation system of anti-u and BCGF, stimulation 
of small B cells with low doses of anti-# alone activates the cells and induces an 694  CYCLOSPORIN  A  AND  HUMAN  B  CELL  ACTIVATION 
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F]CURE 2.  Time dependence of CsA-mediated inhibition of B cell proliferative responses to 
costimulation with anti-# plus BCGF. Small B cells separated from tonsillar mononuclear cells 
were cultured with anti-# (15 #g/ml) plus BCGF (25% voi/vol). CsA (200 ng/ml) was added 
to the cultures at various times, and incorporation of [SH]thymidine was measured after 72 h 
of incubation.  Cultures  were  pulsed  with  1  #Ci  of [3H]thymidine  over  the  last  16  h  of 
incubation. Data represent the mean (+ SEM) of triplicate cultures. 
increase in cell size (9).  Cells stimulated by anti-# started to enlarge within  8 h 
and achieved their maximal volume at 24-36 h (9). In order to examine whether 
CsA  inhibits  enlargement  of B  cells induced  by low concentrations  of anti-#, 
small B cells prepared from tonsillar BCE fractions by elutriation were stimulated 
by anti-# for 36 h  with or without various concentrations of CsA, and cell sizes 
of cultured  cells  were  determined  by a  Coulter  Channelyzer.  Although  cells 
cultured in medium alone enlarged to some extent, a significant increase in cell 
size and  generation  of large  cells was observed in  cultures  stimulated  with  15 
#g/ml anti-# (Table I). When CsA was added to the cultures at a concentration 
of 10-1,000 ng/ml, substantial reduction of both mean volume of cultured cells 
and the number of large cells in the culture were observed (Table I). These data 
demonstrate  that  CsA interferes  with the ability of small  B cells to increase in 
size in response to anti-# stimulation. 
CsA bzhibits RNA Synthesis As Well As DNA Synthesis of Small B Cells Stimulated by 
Anti-#  With  or  Without  BCGF.  In  order  to  study  the  effect of CsA  on  RNA 
synthesis vs. DNA synthesis of B cells activated by anti-# with or without BCGF, 
small B cells were stimulated by anti-#, BCGF, or anti-# plus BCGF in the absence 
or  presence  of 200  ng/ml  CsA,  and  incorporation  of [3H]uridine  and  [3H]- 
thymidine was measured at various times after initial incubation (Fig.  3).  In the 
absence of BCGF, incorporation of [3H]uridine by anti-#-stimulated B cells began 
within 8 h, reached maximal response at 16-30 h, and then the response declined. 
Addition of CsA (200 ng/ml)  inhibited these responses by >60%.  No incorpo- 
ration  of [~H]thymidine by anti-#-stimulated  B  cells was observed during  72-h 
culture with or without CsA (Fig.  3A). In the presence of BCGF, incorporation 
of [~H]uridine by anti-#-stimulated  B cells also started within 8 h and increased 
until  the  termination  of the  incubation.  CsA reduced  the  response  by >50%. 
Incorporation  of [3H]thymidine  by the  same  B  cells  started  --~36-40  h  after 
initial  incubation  and  increased  up to the  end  of the  culture.  CsA completely 
suppressed this response (Fig. 3 C). Stimulation of small B cells by BCGF with or MURAGUCHI  ET  AL.  695 
TABLE  I 
Effect of CsA on Cell Enlargement of Resting B Cells Stimulated by Low-Concentration  Anti-t~ 
Culture 
Exp.  1  Exp. 2 
Mean vol*  Large cells*  Mean vol*  Large cells* 
#ms  %  #m  3  % 
Before culture  175  < l 0  170  < I 0 
After 36 h culture 
Control  224  26  226  28 
Anti-#  ~  315  60  275  48 
Anti-p +  CsA (1,000) !  182  10  202  28 
Anti-# +  CsA (100)  221  25  201  23 
Anti-# +  CsA (10)  236  23  210  28 
Anti-# +  CsA (1)  253  45  237  36 
Anti-# +  CsA (0.1)  281  54  280  51 
* Cell volume of viable cells recovered from  the cultures or before culture were  determined by 
Coulter channelizer. 
* Percentage  of large  cells (cells larger  than  mean  volume  +  1  SD  of cells before  culture)  were 
enumerated by a Coulter Channelyzer. 
Cultures were pulsed by 0.1% of ethanol alcohol with or without anti-# (15 ~g/ml). 
! Various concentrations of CsA (0.1-1,000 ng/ml) were added to the culture from initial incubation, 
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FIGURE 3.  Effect of CsA on RNA synthesis and DNA synthesis of small B cells stimulated by 
anti-# with or without BCGF. Small B cells separated from tonsiUar mononuclear cells were 
stimulated by anti-# (15  #g/ml),  BCGF (25%  vol/vol) or anti-# plus  BCGF in the culture 
containing 0.02% ethanol (O) or containing 200 ng/ml of CsA (e). As a control, small B cells 
were also cultured with 0.02% ethanol alone (A) or with 200 ng/ml CsA alone (&). Cultures 
were pulsed with  1 #Ci/well of [3H]uridine or  1 #Ci/well of [SH]thymidine for 6  h  before 
harvesting. 
without  CsA  induced  no  incorporation  of [3H]uridine  or  [SH]thymidine  (Fig. 
3B).  These  results  demonstrate  that (a) although  low  concentrations  of anti-~ 
can induce RNA synthesis in small B cells, it cannot induce DNA synthesis unless 
BCGF is present; (b) CsA inhibits RNA synthesis of small B cells in response to 696  CYCLOSPOR1N  A  AND  HUMAN  B  CELL  ACTIVATION 
anti-# in the presence or absence of BCGF; and (c) although BCGF by itself does 
not directly stimulate B cells to initiate RNA synthesis or DNA synthesis, it does 
synergize with anti-# and stimulates B cells to initiate DNA synthesis. The critical 
time for the effect of BCGF may be 24-36 h after anti-# stimulation. These data 
suggest  that  CsA  inhibits  DNA  synthesis  of small B  cells in  response to anti-# 
plus BCGF because the drug inhibits RNA synthesis by which small B cells can 
be induced to acquire the responsiveness to BCGF. 
Differential Sensitivity of Resting B Cells and Activated  B Cells to CsA.  In order to 
examine  whether  CsA  can  inhibit  BCGF-induced  B  cell  proliferation,  large, 
activated  B  cells  (mean  size  of  280  #m 3)  that  had  been  incubated  with  low 
concentrations of anti-# for 30 h  were stimulated with BCGF for an additional 
42 h with or without CsA. Addition of CsA at a concentration of 5-500 ng/ml 
did  not  significantly  suppress  the proliferative response of activated  B  cells to 
BCGF, although this range of concentrations of CsA completely suppressed the 
B cell proliferative response of resting B cells to anti-# and BCGF (Fig. 4). These 
data indicate that once resting B cells were activated by triggering signals such 
as  anti-#,  CsA  did  not  interfere  with  the  ability  of these  activated  B  cells  to 
respond to proliferating signals such as BCGF. 
CsA Does Not Interfere With the Ability of  Proliferating  Cells to Respond to BCDF.  It 
has  been  shown  that  SAC  causes  B  cell  proliferation  in  a  T  cell-independent 
fashion,  and  T  cells  or  T  cell-derived  factors  such  as  BCDF  stimulate  SAC- 
activated  proliferating B  cells to differentiate into  ISC  (11).  In order to study 
the effect of CsA on BCDF-induced cell differentiation, activated B cells which 
had been precultured with SAC for 3 d were cultured with BCDF in the presence 
or absence of CsA,  and  PFC were enumerated  after an additional  3-d culture 
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FIGURE  4.  Differential  sensitivity of resting B cells and activated  B cells to CsA. Activated  B 
cells, whose  s  mean  size was 280 #m , were prepared by incubation  of small B  cells with anti-# 
for  30  h.  These  activated  B  cells  were  recultured  with  BCGF  for  an  additional  42  h.  0.1% 
ethanol  or various concentrations  of CsA were added  to the second  culture.  Resting  B  cells, 
whose mean size was 170 um 3, were cultured with anti-u (15 ug/ml) plus BCGF (25% vol/vol) 
for  72 h. 0.1% of ethanol  or various concentrations  of CsA  were added  to the cultures.  All 
cultures were pulsed  by  1 #Ci/well  of [SH]thymidine  over the last 6  h of incubation.  Control 
response of activated B  cells to BCGF was 8,320 __. 560 cpm; background response was 630 _+ 
110  cpm.  Control  response  of resting  B  cells  to  anti-#  plus  BCGF  was  12,020  +  450  cpm; 
background  response to anti-u alone was 820 __ 50; background response to BCGF alone was 
820 _+ 210. MURAGUCH1  ET  AL.  697 
(Table II). BCDF induced significant numbers of PFC, and the addition of CsA 
(1-1,000  ng/ml)  into  the cultures  showed little or no inhibitory effect on the 
induction of PFC. These data show that CsA does not interfere with the ability 
of activated  B  cells  to  differentiate  into  ISC  in  response  to  T  cell-derived 
differentiation factors. 
Discussion 
The present study has demonstrated that CsA has selective suppressive effects 
on the activation vs. proliferation and differentiation phases of the B cell cycle. 
It has been clearly shown that CsA interferes with the ability of the small resting 
B cells to respond to an initial activation signal delivered via its slg by anti-#.  In 
contrast, CsA does not interfere with the ability ofa B cell that has been activated 
by anti-# stimulation to progress to DNA synthesis in response to a proliferative 
signal delivered by BCGF. Furthermore,  it has been demonstrated that once B 
cells are  activated  and  are  proliferating,  they can  then  respond  to  BCDF  by 
differentiating  into  ISC.  This  response  of activated  B  cells  to  differentiation 
factors is resistant to the suppressive effects of CsA. 
Previous studies on the immunosuppressive effects of CsA indicated that the 
drug acted selectively on T  cells with little if any direct effect on B cell function. 
It was shown that CsA inhibited T  cell proliferative responses and the induction 
of cytotoxic cells in mixed lymphocyte reactions (19-24). Studies on the binding 
of  CsA  to  lymphocyte  populations  also  suggested  that  a  receptor  for  CsA 
analogues in both mouse and  man was present in greater quantities  on T  cells 
than on B cells (34, 35). Paavonnen et al. (25, 26) first claimed that CsA interfered 
with  the  ability  of both  human  T  and  B  cells  to  generate  Ig-secreting  cells. 
Recently, selective effects of CsA on functional B cell subsets have been reported 
in the mouse (27, 28). It has also been well known that CsA favors proliferation 
of Epstein-Barr virus-positive lymphoblastoid human  B cells (36, 37). Although 
recent studies in man (38, 39) suggest that CsA modulates T  ceil-independent B 
cell responses to SAC and/or anti-# antibody, the role of CsA on human B cell 
TABLE  II 
Effect of CsA on BCDF-Induced B Cell Differentiation 
Culture with:* 
PFC/welI* 
No  With 
BCDF  BCDF 
Nil 
CsA 
0  (0)  120  (12) 
l  ng/ml  0  (0)  108  (14) 
10  0.6(0.6)  112  (5.2) 
100  3.4 (2.4)  99.4 (9.4) 
1,000  2.6 (1.4)  100  (4.2) 
1o,ooo  o  (o)  o  (o) 
* Small tonsillar B cells were precultured with SAC  for  3  d,  harvested, 
washed, and recultured (3  ×  104/well) in the presence or absence of 
BCDF (10% vol/vol) with various concentrations of CsA (1 ng/ml to 10 
#g/ml). 
* PFC were enumerated after 3 d incubation. The data represent the mean 
number (SEM) of PFC/well of triplicate cultures. 698  CYCLOSPORIN A AND HUMAN B CELL ACTIVATION 
function has not been clearly determined. In the present study, we examined the 
direct  effects of CsA  on  purified  human  B  cells and  demonstrated  that  CsA 
inhibited  human  B cell  proliferative  responses to either  SAC or costimulation 
with anti-/s  and BCGF. CsA suppressed the response of B cells to costimulation 
with anti-/s plus BCGF at 50- to 100-fold lower concentrations than are required 
for the suppression of SAC-induced B cell proliferation  (Fig.  1). This finding is 
similar to that of Dongworth and Klaus (28), in the murine system. In that study, 
the  authors  demonstrated  that  CsA  suppressed  the  proliferative  responses  of 
murine B cells to anti-/s antibody at 300- to 400-fold lower concentrations than 
are required to inhibit  B cell proliferation  induced  by lipopolysaccharide.  One 
possible interpretation  drawn from these data is that there are two distinct B cell 
subsets: one responds to an anti-/s  signal and is more sensitive to CsA, and the 
other responds to SAC in man  or LPS in mouse and  is more resistant  to CsA. 
However, this does not rule out the possibility that anti-/s and SAC (in man) or 
lipopolysaccharide (in  mouse) stimulate  the same  B cells to proliferate  via two 
biochemically distinct triggering  mechanisms, one of which is CsA sensitive and 
the other CsA resistant. 
A  point  of particular  interest  that  emerged  from  the  present  study  is  the 
observation  that  B  cells  were  differentially  sensitive  to  CsA  on  the  basis  of 
sequential activation steps induced by anti-/s  and BCGF: the early phase of B cell 
activation  triggered  by anti-/s  stimulation  was sensitive  to  CsA,  while  the  late 
phase  in  B  cell  activation,  namely,  the  proliferation  triggered  by BCGF,  was 
resistant  to  the  drug.  In  the  present  study,  it  has  been  shown  that  (a)  CsA 
inhibited human  B cell proliferative responses to costimulation  with anti-/s  plus 
BCGF, (b) the  inhibition  by CsA  was found only when  CsA was added  to  the 
culture within 24 h from initial incubation, (c) CsA inhibited cell enlargement of 
small  B  cells stimulated  by anti-/s,  and  (d)  CsA inhibited  the  increase  of RNA 
synthesis induced by anti-u. These data substantiate the concept that CsA exerts 
its  suppressive  effects  on  B  cell  proliferation  by selectively  inhibiting  a  well- 
defined phase of the B cell cycle in that  it interferes with the ability of small B 
cells to become activated, whereas B cells preactivated by anti-u stimulation were 
resistant to the drug in the initiation  of DNA synthesis induced by BCGF (Fig. 
4). 
We have presumed that stimulation of human B cells by SAC or anti-Ig induces 
BCGF receptors on the cell membrane, and BCGF delivers a signal for prolifer- 
ation to these activated,  BCGF-responsive B ceils (8,  9,  12).  Thus, it is possible 
that CsA inhibits the induction  of functionally active BCGF receptors although 
direct evidence must await binding assays employing radiolabeled BCGF. In this 
regard, analogous studies employing CsA have been performed delineating the 
various phases  of the  cell  cycle in  mouse and  human  T  cells after  binding  of 
ligands such as antigens or lectins to the T  cell membrane (23, 24). These reports 
suggest that  lectins or alloantigens  can activate resting T  cells to express func- 
tional receptors for T  cell growth factor (TCGF), and that CsA interferes with 
the ability of resting T  cells to become activated, while preactivated T  cells or 
TCGF-dependent  T  cells are resistant  to CsA in the induction  of proliferation 
triggered by TCGF. 
Another point that emerged from the present study is that although low doses MURAGUCH!  ET  AL.  699 
of anti-tt stimulate small  B cells to initiate  RNA synthesis, they cannot induce 
DNA synthesis unless BCGF is added. Kinetic studies have revealed that RNA 
synthesis by anti-#-stimulated B cells in the absence of BCGF started within 8 h, 
reached maximal response by 24 h, and the response declined at 36 h or later. 
On  the  other  hand,  in  the  presence of BCGF,  these anti-t~-activated  B  cells 
initiated additional RNA synthesis at 24-36 h that was followed by the initiation 
of DNA  synthesis (Fig.  3).  This  finding is  relevant  in  light  of our  previous 
observations that human resting B cells showed sequential requirements for cell 
cycle progression following activation by anti-Ig (9).  We have shown that small 
resting B cells increased in cell size within  36  h  of anti-/~ stimulatiori without 
incorporation of [~H]thymidine, and these anti-#-activated B cells then acquired 
responsiveness to the proliferative signal delivered by BCGF (9). Thus, it seems 
likely that  anti-u  stimulates  small  resting  (Go  phase)  B  cells  to  initiate  RNA 
synthesis concomitant with cell enlargement within 24 to 36 h, thereby driving 
these cells to a  Gla phase.  BCGF  may push these activated G~A phase B  cells 
through G~B phase into S phase. These findings substantiate the observations of 
DeFranco et al.  (4) in the murine system who demonstrated that all murine B 
cells were stimulated by low dose anti-# to become larger (i.e., to proceed from 
Go phase to G~ phase of the cell cycle) and that a  subpopulation of these cells 
entered S phase in response to high concentrations of anti-# or lipopolysaccha- 
ride. 
Finally, the present study demonstrated that differentiative responses of acti- 
vated human B cells to BCDF were not inhibited by CsA. We showed that SAC- 
activated B cells could differentiate normally into ISC in response to BCDF in 
the presence of CsA (Table  II).  These findings are compatible with  those of 
Paavonen  et  al.  (26).  These  authors  showed  that  CsA  suppressed  pokeweed 
mitogen- or SAC-induced PFC response of human peripheral blood mononuclear 
cells when CsA was present throughout the 6-d culture. However, CsA had no 
effect on  PFC responses when added to the culture at day 4  or later.  These 
findings suggest that CsA preferentially inhibited blastogenesis of human B cells 
with minimal effect on the differentiative phase. 
Thus, the present study has employed a pharmacologic approach to dissect the 
distinct stages of human B cell proliferation and has confirmed our model of the 
clear-cut dichotomy between the activation and proliferation phases of the B cell 
cycle. Furthermore, since CsA is being used with greatly increasing frequency as 
an immunosuppressive agent in man, particularly in the prevention and treatment 
of transplanted allografts, it is critical to appreciate the full scope of the immu- 
noregulatory potential of this important therapeutic agent. 
Summary 
The effect ofcyciosporin A (CsA), a fungal metabolite with immunosuppressive 
properties, on the induction of human B cell proliferation and differentiation, 
has been described. CsA had a selective inhibitory effect on the activation phase 
of the cell cycle vs. the proliferation phase following preactivation of the cells. 
Cell enlargement and RNA synthesis of small resting B cells triggered by anti-~ 
were inhibited by addition of CsA (5-500 ng/ml). The inhibitory effect of CsA 
was found only when the drug was added within 24 h of initiation of culture. In 700  CYCLOSPORIN  A  AND  HUMAN B CELL ACTIVATION 
marked contrast, once small B cells were activated by anti-#, the resulting large, 
activated B cells could be induced to initiate DNA synthesis by incubation with 
B cell growth factor (BCGF), and addition of CsA (1-1,000 ng/ml) to the culture 
did not suppress  this  BCGF-induced B  cell  proliferation.  Addition of CsA  to 
cultures of B cells which had been preactivated with Staphylococcus aureus Cowan 
strain I (SAC) and were already proliferating did not suppress B cell differentia- 
tion factor (BCDF)-induced differentiation of these cells. 
Thus,  these  data indicate that  CsA  can  be  used as a  pharmacologic tool  to 
dissect out human B cell responses into two distinct steps: (a) the initial activation 
step  induced  by  anti-Ig,  which  is  characterized  by  cell  enlargement,  RNA 
synthesis, and expression of receptors for BCGF; and (b) the proliferative step 
induced by BCGF in these preactivated B cells that undergo DNA synthesis and 
can then go on to differentiate in the presence of BCDF.  In this regard,  CsA 
selectively suppresses  an  early  step  of human  B  cell  activation  and  has  little 
inhibitory effect on the subsequent factor-dependent proliferation and differen- 
tiation. 
Received  for publication 2 May 1983 and in revised  form  7June 1983. 
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